COVID-19 pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients in treatment group will receive hydroxychloroquine 200 mg (Tehran Daroo) twice daily + Lopinavir/Ritonavir 200-50 mg (Hetero Labs Limited) 2 Tab twice dail
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients between 18 and 65 years old. Laboratory confirmed COVID-19 (Corona Virus Disease-19) with RT-PCR (Real-Time Polymerase Chain Reaction). Severely ill patients. Bilateral pulmonary infiltration. SPO2 (Peripheral Capillary Oxygen Saturation) less than 90% (at rest with nasal cannula 3-4 L/min and FIO2 less than 30-40 L/min). Signed consent form.
Exclusion criteria
Exclusion criteria: Allergy reaction while injecting IVIG with severe extravasation and anaphylactic shock. Mildly ill patient. Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Need for mechanical ventilation. Timepoint: Daily until discharge. Method of measurement: Medical record.;Need of admission to critical care unit. Timepoint: Daily until discharge. Method of measurement: Medical record.;Death. Timepoint: From first day of admission until 28 days. Method of measurement: Medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of symptoms. Timepoint: First day of study then 7 and 14 days after the beginning of the study. Method of measurement: Medical record.;Lung radiology changes. Timepoint: At admission time and 7 and 14 days later. Method of measurement: Computed tomography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPayam Tabarsi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed